Loading…
Biotech developing a bifunctional EGFR/TGF-beta-trap antibody (ficerafusp alfa) for head-and-neck and other solid tumors.
Biotech developing a bifunctional EGFR/TGF-beta-trap antibody (ficerafusp alfa) for head-and-neck and other solid tumors.
Has no product revenue and funds trials by selling shares, so each data readout and financing round shapes what it can afford to run. Ficerafusp alfa attacks a tumour in two ways, blocking a growth receptor (EGFR) and neutralising a signal (TGF-beta) that helps tumours hide from the immune system, and it is tested alongside a checkpoint-inhibitor drug.
Moat: none (IP / patents). Pre-commercial; differentiation rests on unproven combined EGFR/TGF-beta mechanism data.
Headquarters: Boston, Massachusetts, US · Founded: 2021 · Employees: 103
Size Bicara Therapeutics (BCAX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $572M, the 2599th largest of 3,117 United States companies the cockpit tracks. Shares closed at $8.65 on 6 Nov 2026.
Performance Over six months the shares fell 61.7%, against -21.6% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Short interest Short interest is 15.6% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$155,000 | -$105,000 | -$56,000 | -$19,000 | -$10,000 |
| EBITDA | -$202M | -$155M | -$82.3M | -$39.9M | -$37.6M |
| Net income | -$185M | -$138M | -$68.0M | -$52.0M | -$37.8M |
| Free cash flow | -$135M | -$107M | -$74.8M | -$46.2M | -$32.3M |
| Capital expenditure | $400,000 | $280,000 | $71,000 | $586,000 | $192,000 |
| Total debt | $1.16M | $1.71M | $738,000 | $657,000 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Bicara Therapeutics BCAX | $572M | -62% | n/a | n/a | n/a | n/a |
| Merck & MRK | $362B | +33% | +5% | 18% | 5.4× | 4.1% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 7.4× | 11.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BCAX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -49.9% | -7.6% | lowest of 21 |
| 6-month return | -61.7% | -21.6% | lowest of 21 |
| Distance from 52-week high | -72.1% | -35.4% | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | 5.0× | 5.5% | -1.1% |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 7.9× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | 6.5× | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | 0.8× | 5.0% | +5.0% |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 2.0× | 14.8% | +9.7% |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | 20.8× | n/a | n/a |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 6.4× | 27.9% | +15.8% |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 2.9× | -11.1% | +8.8% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 1.4× | -3.2% | +4.1% |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | 62.6× | n/a | n/a |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 0.5× | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |